The significance of the study:
Given that: (1) 15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD; and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.
Research findings to Therapeutic opportunity:
This study suggests, for the first time, that a chocolate-derived compound monomeric cocoa catechin may aid in the treatment of NAFLD. Monomeric cocoa catechin, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, pharmacological formulations encompassing “Monomeric cocoa catechin or its analogs, either alone or in combination with other drugs,” may be used to treat NAFLD.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by Dr. L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Monomeric cocoa catechin decrease the expression of HMGCR to prevent progression of NAFLD?
# Research cooperation
For purchase and payment details, you may reach us at firstname.lastname@example.org
* Research cooperation
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Eating dark chocolate may lower cholesterol and triglyceride levels: Cholate-based therapy for Non-alcoholic fatty liver disease (NAFLD): Monomeric cocoa catechins, found in dark chocolate, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down-regulation of its target gene, 3/September/2018, 12.15 am, Genome-2-Biomedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, drop us a line at email@example.com